{"entity":{"id":"nct07124117","kind":"trial","name":"A Study Evaluating OBI-902 in Participants With Advanced Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of OBI-902 in advanced solid tumours, run by OBI Pharma, Inc, now recruiting.","summary":"A Study Evaluating OBI-902 in Participants With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT07124117 by OBI Pharma, Inc, with 147 participants planned, started 2025-08-04 and due to reach its primary completion in 2029-02-08. Interventions recorded: OBI-902.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07124117","url":"https://clinicaltrials.gov/study/NCT07124117"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07124117","phase":"1/2","setting":"A Phase 1/2, Open-Label, Dose-Escalation and Cohort-Expansion Study Evaluating the Safety, Pharmacokinetics, and Therapeutic Activity of OBI-902 in Participants With Advanced Solid Tumors","sponsor":"OBI Pharma, Inc","enrolled":147,"outcomes":[]},"route":"/trials/nct07124117/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"obi-902","kind":"drug","name":"OBI-902","route":"/drugs/obi-902/"}]}}